ESMO® 2026 Highlights: Presenter Vignettes – Gunhild Von Amsberg

Dr. Gunhild Von Amsberg

Gunhild Von Amsberg

MD

University Cancer Center Hamburg

2217RO

Updated results from the phase 1b/2 KEYNOTE-365 cohort I: pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)